BFC Planning’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35 Hold
61
– – ﹤0.01% 3430
2026
Q2
$97 Hold
61
– – ﹤0.01% 3352
2026
Q1
$13 Hold
61
– – ﹤0.01% 3016
2025
Q4
$96 Hold
61
– – ﹤0.01% 3092
2025
Q3
$65 Hold
61
– – ﹤0.01% 2859
2025
Q2
$98 Hold
61
– – ﹤0.01% 2626
2025
Q1
$74 Hold
61
– – ﹤0.01% 2614
2024
Q4
$115 Hold
61
– – ﹤0.01% 2542
2024
Q3
$326 Buy
+61
New +$446 ﹤0.01% 2500

Other funds holding OTLK

BFC Planning's OTLK Position: Q3 2026 in Review

BFC Planning held its Outlook Therapeutics (OTLK) position steady in Q3 2026 at 61 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

BFC Planning first reported a position in OTLK in Q3 2024 and has held it in 9 quarters since. The position peaked at $326 in Q3 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

  • BFC Planning held 61 shares of Outlook Therapeutics worth $35 as of Q3 2026.
  • BFC Planning left its Outlook Therapeutics share count unchanged in Q3 2026.
  • Outlook Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3430 holding.
  • BFC Planning first reported a position in Outlook Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Outlook Therapeutics position peaked at $326 in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.